TLC-3595 / Shionogi, OrsoBio  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TLC-3595 / OrsoBio
NCT05665751: A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance

Recruiting
2
75
RoW
TLC-3595 Dose 1, TLC-3595 Dose 2, Placebo
OrsoBio, Inc
Insulin Resistance
03/24
05/24

Download Options